Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$36.43 - $49.4 $8.9 Million - $12.1 Million
-244,208 Reduced 37.93%
399,637 $15.8 Million
Q3 2022

Nov 14, 2022

BUY
$40.66 - $53.03 $262,135 - $341,884
6,447 Added 1.01%
643,845 $30 Million
Q2 2022

Nov 14, 2022

BUY
$40.85 - $77.67 $100,205 - $190,524
2,453 Added 0.39%
637,398 $27.9 Million
Q2 2022

Sep 13, 2022

SELL
$40.85 - $77.67 $118,587 - $225,476
-2,903 Reduced 0.47%
610,938 $26.8 Million
Q2 2022

Aug 02, 2022

BUY
$40.85 - $77.67 $73,203 - $139,184
1,792 Added 0.29%
613,841 $27 Million
Q1 2022

Nov 14, 2022

BUY
$59.95 - $92.06 $1.44 Million - $2.21 Million
24,007 Added 3.93%
634,945 $45.9 Million
Q1 2022

Sep 13, 2022

BUY
$59.95 - $92.06 $18,224 - $27,986
304 Added 0.05%
612,049 $44.3 Million
Q1 2022

May 09, 2022

BUY
$59.95 - $92.06 $5.25 Million - $8.07 Million
87,633 Added 16.72%
611,745 $44.3 Million
Q4 2021

Jan 27, 2022

BUY
$81.07 - $121.29 $12.7 Million - $18.9 Million
156,109 Added 42.42%
524,112 $42.5 Million
Q3 2021

Nov 12, 2021

BUY
$101.99 - $166.36 $3.08 Million - $5.02 Million
30,203 Added 8.94%
368,003 $42.8 Million
Q2 2021

Jul 29, 2021

BUY
$141.6 - $179.06 $2.67 Million - $3.37 Million
18,845 Added 5.91%
337,800 $56 Million
Q1 2021

May 14, 2021

BUY
$132.81 - $182.18 $11.7 Million - $16 Million
87,967 Added 38.08%
318,955 $44.5 Million
Q4 2020

Feb 12, 2021

BUY
$138.17 - $184.34 $1.23 Million - $1.65 Million
8,925 Added 4.02%
230,988 $40 Million
Q3 2020

Nov 16, 2020

BUY
$114.09 - $145.51 $183,114 - $233,543
1,605 Added 0.73%
222,063 $30.9 Million
Q2 2020

Aug 14, 2020

BUY
$89.45 - $129.85 $19.7 Million - $28.6 Million
220,458 New
220,458 $26.3 Million

Others Institutions Holding NVRO

About NEVRO CORP


  • Ticker NVRO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,387,800
  • Market Cap $173M
  • Description
  • Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...
More about NVRO
Track This Portfolio

Track Brown Advisory Inc Portfolio

Follow Brown Advisory Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brown Advisory Inc with notifications on news.